And thank you for your kind comments. I too mainly invest in disruptive technologies, and in particular bio-techs, as I can better use my own background, and skill set, in this sector. I would flounder in the mining sector ... a different world.
I also agree that IMU has a massive upside, ... if the incredible science all comes together. To me it looks like 2025 may well be the year of IMU, though, to be honest, I thought it may have arrived earlier with our B-Cell technology. That's another story.
As you so rightly state in another post ... "Trials on humans of course take time to establish the optimum dosages, confirm safety and of course efficacy … and sadly for many ASX investors, patience is in short supply".
If any ''visiting' HC reader were to skim the IMU threads for the first time, they would be confronted by a wave frustration, and sometimes the anger, of may posters. As you say "patience is in short supply".
The issues many investors face here would be similar to the issues I would face in the mining sector ... I don't have a good handle on those processes and certainly no understanding of the time frames involved.
Medical science, and those explorers trying to carefully pick their way at the 'cutting edge', must tread very softly. "Primum non nocere" (First, do no harm). This is a slow race, and one that many here don't fully comprehend when they first enter the world of the bio-tech. Even an Accelerated Approval (AA), must follow very strict guidelines and its own rigid timeline.
I am actually involved in a number trials, and one I will mention, was 'concepted' in 2015 and began enrolling in 2016. As of December 2024, we still do not have a full data readout, so obviously, the 'unpacking' is still to come. This is almost a decade ... for a trial that was planned to take a maximum of 4 years !!! It's nobody's fault, the team has not messed up, it just that many things can impact your trial. What IMU are trying to do, with the CF33 suite, not to mention azer-cel, is so many levels more complex than the trial I mention above. SO ... MANY ... LEVELS !
I am invested in NEU and MSB, and fortunately, I now sit solidly in the 'green' with both. I can tell you that these 'over-night successes' took decades! Yes decades, before they achieved FDA approvals and went green.
In my opinion, the two critical keys to investing in biotech are ... 1. deep research (dive as deeply as you can into the science and gain a good working understanding) AND 2. patience I can see the frustration here. I can feel it. Now I'm hoping IMU comes good in 2025, then its been worth the wait.
@bluebrando, I must also agree that both Davy and TB are well worth the read ... just for slightly different reasons.
I must also acknowledge @Footmax for his regular and very informative updates. I use these often to get a quick insight, so many thanks Footy.
So now, Merry Christmas to all (no, not you trolls) and a very prosperous IMU New Year. May the 'patience' be with you.
As always, just my opinion.
IMU Price at posting:
3.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)